Table 1 Incidence of new-onset all-grade nonhematologic adverse events in the ruxolitinib group regardless of causality, grouped by treatment time interval
|  | Ruxolitinib (n = 155) | ||||
|---|---|---|---|---|---|
0– < 12 Months | 12– < 24 Months | 24– < 36 Months | 36– < 48 Months | ≥48 Months | |
Event,*n/N (%) | |||||
 Fatigue | 43/148.5 (29.0) | 14/92.0 (15.2) | 10/65.5 (15.3) | 5/45.0 (11.1) | 7/21.0 (33.3) |
 Diarrhea | 41/147.5 (27.8) | 6/89.0 (6.7) | 7/65.0 (10.8) | 5/46.5 (10.8) | 3/20.5 (14.6) |
 Ecchymosis | 31/146.0 (21.2) | 10/96.0 (10.4) | 4/70.0 (5.7) | 1/55.0 (1.8) | 1/25.0 (4.0) |
 Dyspnea | 28/146.0 (19.2) | 10/98.5 (10.2) | 2/70.0 (2.9) | 2/54.5 (3.7) | 3/25.0 (12.0) |
 Dizziness | 26/144.0 (18.1) | 10/96.0 (10.4) | 2/66.5 (3.0) | 1/49.5 (2.0) | 1/21.5 (4.7) |
 Pain in extremity | 26/144.5 (18.0) | 6/97.0 (6.2) | 3/71.0 (4.2) | 2/51.5 (3.9) | 1/21.5 (4.7) |
 Peripheral edema | 26/145.5 (17.9) | 7/99.5 (7.0) | 8/75.0 (10.7) | 3/53.5 (5.6) | 2/23.0 (8.7) |
 Headache | 24/144.5 (16.6) | 5/99.0 (5.1) | 3/75.0 (4.0) | 4/58.0 (6.9) | 4/26.0 (15.4) |
 Nausea | 24/144.5 (16.6) | 7/102.5 (6.8) | 4/79.0 (5.1) | 5/61.0 (8.2) | 4/27.5 (14.5) |
 Constipation | 21/145.0 (14.5) | 10/105.0 (9.5) | 8/78.5 (10.2) | 4/56.5 (7.1) | 4/25.0 (16.0) |
 Abdominal pain | 20/144.5 (13.8) | 6/106.0 (5.7) | 3/84.0 (3.6) | 4/66.0 (6.1) | 4/29.5 (13.6) |
 Insomnia | 20/144.5 (13.8) | 7/104.5 (6.7) | 3/80.0 (3.8) | 1/62.5 (1.6) | 1/28.0 (3.6) |
 Vomiting | 20/145.5 (13.7) | 3/105.5 (2.8) | 2/82.5 (2.4) | 4/64.5 (6.2) | 4/29.0 (13.8) |
 Pyrexia | 20/148.0 (13.5) | 8/109.5 (7.3) | 7/82.5 (8.5) | 3/62.0 (4.8) | 2/27.5 (7.3) |
 Cough | 19/145.0 (13.1) | 14/105.5 (13.3) | 3/74.5 (4.0) | 4/58.5 (6.8) | 4/26.0 (15.4) |
 Arthralgia | 17/144.0 (11.8) | 6/103.0 (5.8) | 6/75.5 (7.9) | 6/53.5 (11.2) | 3/21.5 (14.0) |
 Muscle spasms | 14/143.0 (9.8) | 3/105.0 (2.9) | 7/81.0 (8.6) | 6/58.0 (10.3) | 1/23.0 (4.3) |
 Back pain | 13/143.0 (9.1) | 11/106.5 (10.3) | 0 | 4/58.0 (6.9) | 3/25.5 (11.8) |
 Night sweats | 13/143.0 (9.1) | 3/105.5 (2.8) | 3/81.5 (3.7) | 1/61.5 (1.6) | 4/28.0 (14.3) |
 Pneumonia | 13/145.0 (9.0) | 7/110.0 (6.4) | 3/82.5 (3.6) | 3/65.0 (4.6) | 5/30.5 (16.4) |
 Upper respiratory tract infection | 11/143.0 (7.7) | 12/108.0 (11.1) | 4/74.5 (5.4) | 4/55.0 (7.3) | 3/24.0 (12.5) |
 Fall | 7/143.5 (4.9) | 2/111.5 (1.8) | 1/87.0 (1.1) | 3/68.5 (4.4) | 4/30.5 (13.1) |
 Musculoskeletal pain | 7/143.0 (4.9) | 5/112.0 (4.5) | 7/85.5 (8.2) | 2/62.5 (3.2) | 4/29.0 (13.8) |
 Pruritus | 7/142.5 (4.9) | 8/110.5 (7.2) | 1/81.0 (1.2) | 1/63.5 (1.6) | 3/29.0 (10.3) |
 Herpes zoster | 3/143.5 (2.1) | 4/115.5 (3.5) | 3/87.5 (3.4) | 3/66.0 (4.5) | 3/29.0 (10.3) |
 Squamous cell carcinoma | 0 | 1/116.5 (0.9) | 2/91.5 (2.2) | 2/70.5 (2.8) | 4/32.0 (12.5) |